James P Crowley: Key differences between nivolumab or Opdivo and pembrolizumab or Keytruda
James P Crowley, Professor of Medicine emeritus at Brown University, shared a post on LinkedIn:
“Key differences between nivolumab or Opdivo and pembrolizumab or Keytruda
These are a few of the main differences between Opdivo and Keytruda: Active ingredient: Opdivo has nivolumab, and Keytruda has pembrolizumab.
Dose schedule: Opdivo infusions are given every 2, 3, or 4 weeks. Keytruda infusions are given every 3 or 6 weeks. Conditions treated: Opdivo and Keytruda can both treat 10 types of cancer. Keytruda also treats several other cancers that Opdivo is not approved to treat.
Although they contain different active ingredients, both Opdivo and Keytruda belong to a class of medications known as programmed death receptor-1 (PD-1) inhibitors. A medication class is a group of drugs that work in a similar way. PD-1 inhibitors are a type of immunotherapy for cancer. Lots of progress for each of these medications in many cancers but a shout out for nivolumab for melanoma and pembrolizumab for bladder cancer in global, randomized clinical trials! Read more.”
More posts featuring James P Crowley.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023